Kelonia Therapeutics Presents First-in-Human Data From Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual Meeting 100% MRD-negative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback